Mirvetuximab Fails to Boost Survival in Platinum-Eligible Ovarian Cancer Christos Evangelou, MSc, PhD June 25, 2026

https://www.medscape.com/viewarticle/mirvetuximab-fails-boost-survival-platinum-eligible-ovarian-2026a1000lka?src= The antibody-drug conjugate (ADC) mirvetuximab soravtansine boosts tumor response when added to standard chemotherapy for patients with platinum-sensitive ovarian cancer, but it does not improve their survival outcomes, according to a phase 2 trial.